Pangaea Oncology, S.A. (BME:PANG)

Market Cap	55.31M -5.3%
Revenue (ttm)	16.73M +68.1%
Net Income	-3.60M
EPS	-0.10
Shares Out	35.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	850
Average Volume	6,716
Open	1.570
Previous Close	1.540
Day's Range	1.570 - 1.570
52-Week Range	1.540 - 1.750
Beta	-0.02
RSI	21.07
Earnings Date	May 12, 2026

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnost...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 159
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2025, Pangaea Oncology's revenue was 16.73 million, a decrease of -0.32% compared to the previous year's 16.79 million. Losses were -3.60 million, 208.3% more than in 2024.